Post
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
Zai Lab has announced that its New Drug Application (NDA) for Augtyro (repotrectinib) has been greenlit by China’s National Medical …
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
Japanese pharma company Takeda has signed an exclusive, worldwide option and licence agreement for AC Immune’s amyloid beta-targeting Alzheimer’s disease …
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Regeneron and Sanofi could soon be adding another indication to its blockbuster immunology drug Dupixent (dupilumab) after the US Food …
Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
Fulcrum Therapeutics has signed a $1bn exclusive licence deal with Sanofi to develop and commercialise the investigational facioscapulohumeral muscular dystrophy …
Dementia Action Week 2024: the future of Alzheimer’s diagnostics
Dementia Action Week 2024, which starts today, shines a spotlight on Alzheimer’s disease, the most common cause of dementia. The approval …
Lula’s progress plan for Brazil: A year on
On 30 May 2023, President Lula da Silva assembled the first South American summit in nearly a decade. In reviving …
Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine
Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine. Starting in 2025, the drugmaker …
RAPT terminates Phase II trials for lead candidate following clinical hold
RAPT Therapeutics has announced plans to terminate two Phase II trials for its lead candidate, zelnecirnon (RPT193), three months after …
Freeline touts positive data for Gaucher disease therapy
Clinical-stage biotech Freeline Therapeutics has announced new positive data affirming the safety and efficacy of its gene therapy FLT201, for …
WestGene wins FDA nod to study mRNA vaccine to treat certain cancers
The US Food and Drug Administration (FDA) has approved an IND to conduct a clinical trial that evaluates an mRNA …
Oral solid dosage manufacturing companies, equipment and market
Oral solid dosage manufacturing companies, equipment and market: Introduction In an industry where precision and compliance are of paramount importance, selecting …
Shionogi secures licence for Maze’s Pompe disease treatment
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’s MZE001, an oral glycogen synthase 1 (GYS1) inhibitor to …
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
Formosa Pharmaceuticals has announced an exclusive licensing agreement with Tabuk Pharmaceuticals, granting the latter exclusive rights to commercialise the clobetasol …
Four ways the vaccine rush will define infectious disease trends for CROs in 2024
The global healthcare sector has witnessed both unprecedented challenges and achievements over the past few years, most notably during the …
Attovia secures $105m to advance development of lead programmes
Attovia Therapeutics has secured $105m in an oversubscribed Series B financing round to expedite the development of its lead programmes …